The new lab testing of the drug vorinostat indicated that the medication is able to cross the blood-brain barrier and reduce the occurrence of metastatic tumors in mice. The study, published in the September 29 online issue of Clinical Cancer Research, demonstrated that vorinostat reduced the development of large metastatic tumors in mice by 62% as compared a group of mice that did not receive the drug. Although vorinostat has been approved by the FDA for the treatment of cutaneous T-cell lymphoma, it has only been used experimentally as a treatment for other cancers.